Hing, Z A <br/><br/>
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.  [electronic resource] 

 -  Leukemia  12 2016 
 - 2364-2372 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2016.136  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--therapeutic use<br/>Hematologic Neoplasms--drug therapy<br/>Heterografts<br/>Humans<br/>Karyopherins--antagonists & inhibitors<br/>Mice<br/>Neoplasm Invasiveness<br/>Receptors, Cytoplasmic and Nuclear--antagonists & inhibitors<br/>Survival Rate<br/>Treatment Outcome<br/>Exportin 1 Protein